Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.gov

Journal of Clinical Pharmacology

Volumn 54, Issue 4, 2014, Pages 432-437

  Stockmann, Chris ^a,b   Sherwin, Catherine M T ^a   Koren, Gideon ^c   Campbell, Sarah C ^a   Constance, Jonathan E ^a   Linakis, Matthew ^a   Balch, Alfred ^a   Varner, Michael W ^a   Spigarelli, Michael G ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

children; infant; obstetric; pharmacology; pregnancy

Indexed keywords

ARTICLE; BEHAVIORAL MEDICINE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); HUMAN; INTERVENTION STUDY; OBSERVATIONAL STUDY; OBSTETRICS; OUTCOME ASSESSMENT; PUBLICATION; QUALITY CONTROL; RISK ASSESSMENT; STUDY DESIGN;

CHILDREN; INFANT; OBSTETRIC; PHARMACOLOGY; PREGNANCY;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; FEMALE; HUMANS; OBSTETRICS; PUBLISHING;

EID: 84898624745     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.212     Document Type: Article

References (35)

1. Koren G, Pastuszak A, Ito S,. Drugs in pregnancy. N Engl J Med. 1998; 338 (16): 1128-1137. (Pubitemid 28227484)
2. Lee E, Maneno MK, Smith L, et al. National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf. 2006; 15 (8): 537-545. (Pubitemid 44336268)
3. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004; 191 (2): 398-407. (Pubitemid 39178690)
4. Headley J, Northstone K, Simmons H, Golding J,. Medication use during pregnancy: data from the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol. 2004; 60 (5): 355-361. (Pubitemid 39062322)
5. Lo WY, Friedman JM,. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol. 2002; 100 (3): 465-473. (Pubitemid 35246132)
6. Mastoianni AC, Faden R, Federman D,. Women and health research: a report from the Institute of Medicine. Kennedy Inst Ethics J. 1994; 4: 55-62.
7. Zajicek A, Giacoia GP,. Obstetric clinical pharmacology: coming of age. Clin Pharmacol Ther. 2007; 81 (4): 481-482. (Pubitemid 46452317)
8. Baylis F,. Pregnant women deserve better. Nature. 2010; 465 (7299): 689-690.
9. Public Law 93-348: National Research Act of 1974. (88 Stat.; Date: 7/12/1974; enacted H.R. 7724). Text from United States Public Laws. Available from: ProQuest® Congressional; Accessed: 6/14/13.
10. Doering PL,. Drug use during pregnancy. Natl Assoc Retail Druggists J. 1992; 53-57.
11. Doering PL, Boothby LA, Cheok M,. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks ? Am J Obstet Gynecol. 2002; 187 (2): 333-339. (Pubitemid 34925565)
12. Boothby LA, Doering PL,. FDA labeling system for drugs in pregnancy. Ann Pharmacother. 2001; 35 (11): 1485-1489. (Pubitemid 33042087)
13. Public Affairs Committee of the Teratology Society. Teratology public affairs committee position paper: Pregnancy labeling for prescription drugs: Ten years later. Birth defects research Part A, Clin Mol Teratol. 2007; 79 (9): 627-630.
14. National Institutes of Health Revitalization Act of 1993. Science and Technology. Vol. Public Law 103-43 (1993).
15. Endicott S, Haas DM,. The current state of therapeutic drug trials in pregnancy. Clin Pharmacol Ther. 2012; 92 (2): 149-150.
16. Ward SP,. Thalidomide and congenital abnormalities. Br Med J. 1962; 2 (5305): 646-647.
17. Hanson JW, Jones KL, Smith DW,. Fetal alcohol syndrome. Experience with 41 patients. JAMA. 1976; 235 (14): 1458-1460.
18. Gill WB, Schumacher GF, Bibbo M, Straus FH II, Schoenberg HW,. Association of diethylstilbestrol exposure in utero with cryptorchidism, testicular hypoplasia and semen abnormalities. J Urol. 1979; 122 (1): 36-39. (Pubitemid 9248408)
19. Zarin DA, Tse T, Ide NC,. Trial registration at ClinicalTrials.gov between May and October 2005. N Engl J Med. 2005; 353 (26): 2779-2787. (Pubitemid 43016817)
20. U.S., National Institutes of Health. ClinicalTrials.gov. The National Library of Medicine. Accessed 28 June 2013 at: http://clinicaltrials.gov/.
21. Tse T, Williams RJ, Zarin DA,. Reporting "ba sic results" in ClinicalTrials.gov. Chest. 2009; 136 (1): 295-303.
22. Bourgeois FT, Murthy S, Pinto C, Olson KL, Ioannidis JP, Mandl KD,. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics. 2012; 130 (2): 285-292.
23. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM,. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. Br Med J. 2012; 344: d7292.
24. Schimmer BP, Parker KL,. 2011. Contraception and pharmacotherapy of obstetrical and gynecological disorders. In:, Brunton LL, Blumenthal DK, Murri N, Dandan RH, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th edition. New York: McGraw-Hill. p 1833-1852.
25. Froster UG, Baird PA,. Maternal factors, medications, and drug exposure in congenital limb reduction defects. Environ Health Perspect. 1993; 101 (Suppl 3): 269-274. (Pubitemid 24014790)
26. Dally A,. Thalidomide: was the tragedy preventable ? Lancet. 1998; 351 (9110): 1197-1199.
27. Anderson GD,. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005; 44 (10): 989-1008. (Pubitemid 41356388)
28. Loebstein R, Koren G,. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther Drug Monit. 2002; 24 (1): 15-22. (Pubitemid 34106725)
29. Kutcher JS, Engle A, Firth J, Lamm SH,. Bendectin and birth defects. II: ecological analyses. Birth defects research Part A, Clin Mol Teratol. 2003; 67 (2): 88-97. (Pubitemid 38222001)
30. Kleppinger CF, Ball LK,. Building quality in clinical trials with use of a quality systems approach. Clin Infect Dis. 2010; 51 (Suppl 1): S111-S116.
31. Institute of Medicine. Assuring data quality and validity in clinical trials for regulatory decision making: workshop report. (1999) Accessed 12 June 2013 from: http://www.nap.edu/openbook.php?record-id=9623.
32. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A,. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA. 2012; 307 (17): 1838-1847.
33. U.S. Food and Drug Administration. Comparison of FDA and HHS human subject protection regulations. 46.102. Definitions. Available at: http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ educationalmaterials/ucm112910.htm. Accessed 12 June 2013.
34. Califf RM,. Better late than never: a welcome publication of tardy clinical trial results. JACC Heart Fail. 2013; 1 (2): 112-114.
35. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC,. The ClinicalTrials.gov results database-update and key issues. N Engl J Med. 2011; 364 (9): 852-860.